Plural Chalcogens Bonded Directly To Piperazine Ring Carbons Patents (Class 544/385)
-
Patent number: 11913059Abstract: An apparatus and method for detecting an analyte of interest using paper spray mass spectrometry includes a spray material; a sample on the spray material including an enzyme of interest; a solvent to hydrate the sample, promote enzymatic activity, and extract analytes of interest from the sample; a substrate specific to the enzyme of interest, wherein any of the spray material and the solvent includes the substrate; a voltage source to apply a voltage to the spray material to create charged droplets of a mixture containing the sample; and a mass spectrometer to perform spectrometry on the droplets to perform any of: identify the analytes of interest in the sample; and measure a level of inhibition in any enzymes contained in the sample.Type: GrantFiled: October 26, 2021Date of Patent: February 27, 2024Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Trevor G Glaros, Elizabeth S Dhummakupt, Phillip M Mach, Daniel O Carmany
-
Patent number: 11872265Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.Type: GrantFiled: January 5, 2021Date of Patent: January 16, 2024Assignee: MANNKIND CORPORATIONInventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
-
Patent number: 11440891Abstract: The disclosed embodiments detail improved methods for the synthesis of diketopiperazines from amino acids. In particular improved methods for the cyclocondensation and purification of N-protected 3,6-(aminoalkyl)-2,5-diketopiperazines from N-protected amino acids. Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid in the presence of a catalyst in an organic solvent. The catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others. The solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others.Type: GrantFiled: May 4, 2020Date of Patent: September 13, 2022Assignee: MANNKIND, CORP.Inventors: John J. Freeman, Adrienne Stamper, Melissa Heitmann
-
Patent number: 11084794Abstract: The present disclosure provides improved methods for controlled cyclization of peptoid dimers to form N,N?-2,5-diketopiperazines (N,N?-2,5-DKPs) with significant selectivity. In at least some examples, selectivity is based on a serendipitous conglomeration of slow exchange of amide rotamers, steric repulsion from the degree of ?-substitution, and the geometric bulk of an amine nucleophile. By varying reaction conditions, the selectivity of the reaction and formation of a particular N,N?-2,5-DKP can be switched. The cyclization works in the presence of a variety of protection groups and diverse functionalities. The teachings herein provide techniques for synthesizing N,N?-2,5-DKPs that can be readily docked with drug candidates for shuttling across the blood brain barrier. This method provides a facile way to produce substituted DKPs containing groups ready for post-modification to include docking drug candidates.Type: GrantFiled: October 30, 2019Date of Patent: August 10, 2021Assignee: Triad National Security, LLCInventors: Robert F. Williams, Paul William Peterson, Robert David Gilbertson, Jurgen G. Schmidt, Charlie E. Strauss
-
Patent number: 10858325Abstract: Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphophoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.Type: GrantFiled: September 10, 2018Date of Patent: December 8, 2020Assignee: MANNKIND, CORP.Inventors: Kelly Sullivan Kraft, John J. Freeman, Paul Serwinski, Vincent Pavia, Otto Phanstiel, Navneet Kaur
-
Patent number: 10604491Abstract: Provided is a method for the synthesis of N-protected 3,6-bis-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.Type: GrantFiled: October 4, 2018Date of Patent: March 31, 2020Assignee: Mannkind corporationInventors: John J. Stevenson, Destardi Moye-Sherman
-
Patent number: 9944609Abstract: A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic ?-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.Type: GrantFiled: November 16, 2015Date of Patent: April 17, 2018Assignee: MannKind CorporationInventors: John J. Freeman, Otto Phanstiel, William Elliot Bay, Kelly Sullivan Kraft
-
Patent number: 9707227Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: February 18, 2010Date of Patent: July 18, 2017Assignee: Ampio Pharmaceuticals, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Patent number: 9040701Abstract: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.Type: GrantFiled: July 29, 2010Date of Patent: May 26, 2015Assignee: LABORATORIOS SALVAT, S.A.Inventors: Ángel Messeguer Peypoch, Alejandra Moure Fernández, Daniel González Pinacho, Isabel Masip Masip, Enrique Pérez Payá, Natividad García Villar, Ester Monlleó Mas, Juanlo Catena Ruiz
-
Publication number: 20150133470Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20150073149Abstract: The disclosed embodiments detail improved methods for the synthesis of diketopiperazines from amino acids. In particular improved methods for the cyclocondensation and purification of N-protected 3,6-(aminoalkyl)-2,5-diketopiperazines from N-protected amino acids. Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid in the presence of a catalyst in an organic solvent. The catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others. The solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Inventors: John J. Freeman, Adrienne Stamper, Melissa Heitmann
-
Patent number: 8912328Abstract: The disclosed embodiments detail improved methods for the synthesis of diketopiperazines from amino acids. In particular improved methods for the cyclocondensation and purification of N-protected 3,6-(aminoalkyl)-2,5-diketopiperazines from N-protected amino acids. Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid in the presence of a catalyst in an organic solvent. The catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others. The solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others.Type: GrantFiled: February 7, 2012Date of Patent: December 16, 2014Assignee: MannKind CorporationInventors: John J. Freeman, Adrienne Stamper, Melissa Heitmann
-
Patent number: 8889099Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.Type: GrantFiled: January 30, 2013Date of Patent: November 18, 2014Assignee: MannKind CorporationInventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
-
Patent number: 8871772Abstract: The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation.Type: GrantFiled: February 23, 2012Date of Patent: October 28, 2014Assignee: Ampio Pharmaceuticals, Inc.Inventor: David Bar-Or
-
Publication number: 20140271888Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: ApplicationFiled: April 11, 2014Publication date: September 18, 2014Applicant: MannKind CorporationInventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
-
Publication number: 20140243530Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.Type: ApplicationFiled: April 30, 2014Publication date: August 28, 2014Applicant: MannKind CorporationInventors: John J. Stevenson, Destardi Moye-Sherman
-
Patent number: 8748609Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.Type: GrantFiled: March 16, 2012Date of Patent: June 10, 2014Assignee: MannKind CorporationInventors: John J. Stevenson, Destardi Moye-Sherman
-
Patent number: 8653085Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.Type: GrantFiled: August 22, 2012Date of Patent: February 18, 2014Assignee: Mankind CorporationInventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
-
Patent number: 8637521Abstract: The present invention discloses multifunctional bioactive compounds of formula (I) constituted of an immunoregulatory portion linked to a stabilizer moiety and pharmaceutical compositions thereof useful in the treatment of immune disorders and hemopoietic disorders such as immune cytopema, multiple myeloma, chronic lymphoid leucosis, lymphocytic lymphomas, lymphosarcomas.Type: GrantFiled: August 1, 2007Date of Patent: January 28, 2014Assignee: Manus Pharmaceuticals (Canada) Ltd.Inventor: Vladislav I. Deigin
-
Publication number: 20130296566Abstract: Reactors, reactor systems and methods for producing particles in a precipitation process are provided. The reactor includes a housing defining a reaction chamber, a stator assembly including two or more stators, a rotor assembly including two or more rotors, the rotor assembly configured for rotation about an axis of rotation relative to the stator assembly, a first inlet to supply a first reactant material to the reaction chamber at a first radial location, a second inlet to supply a second reactant material to the reaction chamber at a second radial location different from the first radial location, wherein the first and second reactant materials react to produce precipitation of particles in the reaction chamber, and an outlet to supply the particles formed in the reaction chamber.Type: ApplicationFiled: July 8, 2013Publication date: November 7, 2013Applicant: MannKind CorporationInventors: Sanket Gandhi, Karen Moraleda, Jadwiga Jachowicz, Michael Zupon
-
Publication number: 20130289278Abstract: Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphosphoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Applicant: MANNKIND CORPInventors: Kelly Sullivan Kraft, John J. Freeman, Paul Serwinski, Vinnie Pavia, Otto Phanstiel, IV, Navneet Kaur
-
Publication number: 20130281664Abstract: The present invention relates to novel Ruthenium catalysts and related borohydride complexes, and the use of such catalysts, inter alia, for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e.Type: ApplicationFiled: October 11, 2011Publication date: October 24, 2013Inventors: David Milstein, Ekambaram Balaraman, Chidambaram Gunanathan, Boopathy Gnanaprakasam, Jing Zhang
-
Publication number: 20130190177Abstract: Disclosed herein is an agricultural agent containing a 2,5-diketopiperazine derivative capable of controlling plant diseases and promoting plant growth or an agriculturally acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 14, 2011Publication date: July 25, 2013Applicants: Kongju National University Industry- University Cooperation Foundation, Republic of Korea (Management: Rural Development Administration)Inventors: Kyung Seok Park, Jin Woo Park, Sang Yeob Lee, Surk Sik Moon, In Seok Hong
-
Publication number: 20130158021Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: October 26, 2012Publication date: June 20, 2013Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Patent number: 8455641Abstract: A method for preparing compounds of the formula (I) by the cyclization of tetraacetic acid alkyl esters of the formula (II) in the presence of ammonia and formamide as well as to the compounds of the formula (II), which are used in this method.Type: GrantFiled: November 23, 2007Date of Patent: June 4, 2013Assignee: Cyathus Exquirere Pharmaforschungs GmbHInventors: Andreas Koch, Erwin Neufellner
-
Publication number: 20130137689Abstract: The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.Type: ApplicationFiled: January 15, 2013Publication date: May 30, 2013Applicant: FAB PHARMA S.A.S.Inventor: FAB PHARMA S.A.S.
-
Patent number: 8450301Abstract: The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description.Type: GrantFiled: December 29, 2006Date of Patent: May 28, 2013Assignee: BASF SEInventors: Eike Hupe, Cyrill Zagar, Matthias Witschel, Toralf Kühn, William Karl Moberg, Liliana Parra Rapado, Frank Stelzer, Andrea Vescovi, Michael Puhl, Robert Reinhard, Bernd Sievernich, Klaus Groβmann, Thomas Ehrhardt, Michael Rack
-
Publication number: 20130131338Abstract: A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 14, 2012Publication date: May 23, 2013Applicant: Glaxo Group LimitedInventor: Glaxo Group Limited
-
Publication number: 20130072684Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: ApplicationFiled: November 14, 2012Publication date: March 21, 2013Applicant: DMI BIOSCIENCES, INC.Inventor: DMI Biosciences, Inc.
-
Publication number: 20130012710Abstract: The disclosed embodiments detail improved methods for the synthesis of diketopiperazines from amino acids. In particular improved methods for the cyclocondensation and purification of N-protected 3,6-(aminoalkyl)-2,5-diketopiperazines from N-protected amino acids. Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid in the presence of a catalyst in an organic solvent. The catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others. The solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others.Type: ApplicationFiled: February 7, 2012Publication date: January 10, 2013Inventors: John J. Freeman, Adrienne Stamper, Melissa Heitmann
-
Patent number: 8314106Abstract: Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.Type: GrantFiled: December 29, 2009Date of Patent: November 20, 2012Assignee: MannKind CorporationInventor: Kelly Sullivan Kraft
-
Publication number: 20120283178Abstract: The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. The present invention provides antidepressants and learning motivation improvers, each comprising a cyclic dipeptide with the 2,5-diketopiperazine structure as an active ingredient.Type: ApplicationFiled: February 26, 2010Publication date: November 8, 2012Applicants: Cerebos Pacific Limited, Suntory Holdings LimitedInventors: Nobuo Tsuruoka, Yoshinori Beppu, Hirofumi Kouda, Hiroshi Watanabe
-
Publication number: 20120253042Abstract: A process for preparing amides by reacting a primary amine and a primary alcohol in the presence of a Ruthenium complex to generate the amide and molecular hydrogen. Primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. Also disclosed are processes for hydrogenation of amides to alcohols and amines; hydrogenation of organic carbonates to alcohols; hydrogenation of carbamates or urea derivatives to alcohols and amines; amidation of esters; acylation of alcohols using esters; coupling of alcohols with water and a base to form carboxylic acids; dehydrogenation of beta-amino alcohols to form pyrazines and cyclic dipeptides; and dehydrogenation of secondary alcohols to ketones. These reactions are catalyzed by a Ruthenium complex which is based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3.Type: ApplicationFiled: May 14, 2012Publication date: October 4, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: David Milstein, Chidambaram Gunanathan, Yehoshua Ben-David, Ekambaram Balaraman, Boopathy Gnanaprakasam, Jing Zhang
-
Publication number: 20120227545Abstract: This invention relates to a process for the recovery of precious metal/s from a precious metal-containing material in an aqueous leach slurry or solution. The process includes the step of contacting the precious metal/s in the leach slurry or solution with a ligand selected from dithiooxamide (rubeanic acid), or a substituted dithiooxamide. The leaching of PGMs, gold and silver from their ores using the ligand of the present invention may take place under aqueous alkaline conditions, avoiding both corrosive acidic conditions and the use of cyanide.Type: ApplicationFiled: July 21, 2010Publication date: September 13, 2012Applicant: ANGLO OPERATIONS LIMITEDInventors: Diandree Padayachee, Makhosazane Chucky Kunene, Marga Retha Burger, Noko Simon Phala
-
Publication number: 20120232079Abstract: The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.Type: ApplicationFiled: October 20, 2010Publication date: September 13, 2012Inventors: Vincent Gerusz, Sonia Escaich, Mayalen Oxoby, Francois Moreau
-
Publication number: 20120225890Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.Type: ApplicationFiled: March 6, 2012Publication date: September 6, 2012Inventors: Alan D. Snow, Beth Nguyen, Gerardo Castillo, Virginia Sanders, Thomas Lake, Lesley Larsen, Rex T. Weavers, Stephen Lorimer, David Larsen, David L. Coffen, Charlotte Coffen
-
Publication number: 20120220596Abstract: The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicants: UWM RESEARCH FOUNDATION, INC., MARQUETTE UNIVERSITYInventors: James M. Cook, David A. Baker, Wenyuan Yin, Edward Merle Johnson, II
-
Publication number: 20120208896Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.Type: ApplicationFiled: January 25, 2012Publication date: August 16, 2012Applicant: Bezwada Biomedical, LLC.Inventor: Rao S. Bezwada
-
Patent number: 8227409Abstract: Disclosed herein are fumaryl diketopiperazine (FDKP) compositions and microparticles having a specific trans isomer content of about 45% to about 65%. The FDKP microparticles can comprise a drug such as an endocrine hormone, including, peptide, including, insulin, glucagon, parathyroid hormones and the like and can be used to make a powder formulation for pulmonary delivery of the drug.Type: GrantFiled: June 11, 2010Date of Patent: July 24, 2012Assignee: MannKind CorporationInventors: Kelly S. Kraft, Karla Somerville
-
Publication number: 20120178935Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.Type: ApplicationFiled: March 16, 2012Publication date: July 12, 2012Applicant: MannKind CorporationInventors: John J. Stevenson, Destardi Moye-Sherman
-
Patent number: 8217047Abstract: The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation.Type: GrantFiled: May 27, 2009Date of Patent: July 10, 2012Assignee: DMI Acquisition Corp.Inventor: David Bar-Or
-
Publication number: 20120164186Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: ApplicationFiled: June 11, 2010Publication date: June 28, 2012Applicant: MANNKIND CORPORATIONInventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
-
Patent number: 8202992Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.Type: GrantFiled: December 8, 2009Date of Patent: June 19, 2012Assignee: MannKind CorporationInventors: John J. Stevenson, Destardi Moye-Sherman
-
Publication number: 20120129939Abstract: Disclosed herein are methods for treating a disease involving ?-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce ?-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce ?-synucleic aggregation; or (3) a compound which inhibits ?-synucleic aggregation in an amount effective to reduce ?-synucleic aggregation. Also disclosed are methods for reducing the amount of ?-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce ?-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce ?-synucleic aggregation; or (3) a compound which inhibits ?-synucleic aggregation in an amount effective to reduce ?-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.Type: ApplicationFiled: March 1, 2010Publication date: May 24, 2012Inventors: Scott A. Small, Nicole Lewandowski, Donald W. Landry, Shi-Xiang Deng
-
Publication number: 20120122868Abstract: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.Type: ApplicationFiled: July 29, 2010Publication date: May 17, 2012Applicant: LABORATORIOS SALVAT, S.A.Inventors: Ángel Messeguer Pyepoch, Alejandra Moure Fernández, Daniel Gonzáles Pinacho, Isabel Masip Masip, Enrique Pérez Payá, Natividad García, Ester Monlleó Mas, Juanlo Catena Ruiz
-
Patent number: 8173809Abstract: The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction. Exemplary prodrugs include the cysteine compound having the formula as well as cystine dimers thereof.Type: GrantFiled: February 9, 2009Date of Patent: May 8, 2012Assignees: Marquette University, UWM Research Foundation, Inc.Inventors: James M. Cook, David A. Baker, Wenyuan Yin, Edward Merle Johnson, II
-
Publication number: 20120108677Abstract: Disclosed are biocompatible, bioresorbable polymers comprising a plurality of monomeric repeating units containing an imine group, wherein the inclusion of said imine group is effective to lower the melt viscosity, the solution viscosity, or both, compared to the same polymer without an imine group.Type: ApplicationFiled: November 1, 2011Publication date: May 3, 2012Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Joachim B. Kohn, Durgadas Bolikal
-
Publication number: 20120014999Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: ApplicationFiled: June 11, 2010Publication date: January 19, 2012Inventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
-
Patent number: 8044056Abstract: A novel adenine compound represented by the formula (1): [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted 6- to 10-membered aryl, etc., L1 and L2 are independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.Type: GrantFiled: March 19, 2008Date of Patent: October 25, 2011Assignees: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca AktiebolagInventors: Yoshiaki Isobe, Tomoaki Nakamura
-
Publication number: 20110144336Abstract: A process for preparing piperazinedione derivatives of the formula I in which R1 is hydrogen, alkyl, alkenyl, alkynyl and alkylcarbonyl, R2 is hydrogen, alkyl, alkenyl, C3-C4-alkynyl and C(?O)R11, R3, R4 are each hydrogen, alkyl and haloalkyl, where the groups may be substituted, which comprises reacting amines of the formula II H2N—R1??II in which R1 is hydrogen and alkyl which may optionally be substituted with N-acylated amino acid derivatives of the formula III in which X is halogen, Y is halogen, alkoxy or phenyloxy which may be substituted and R2, R3 and R4 are each as defined at the outset, under basic conditions in an aqueous solvent.Type: ApplicationFiled: July 30, 2009Publication date: June 16, 2011Applicant: BASF SEInventors: Thomas Zierke, Eike Hupe, Michael Rack, Liliana Parra Rapado, Timo Frassetto